Page last updated: 2024-10-31

mitoxantrone and Carcinoma, Ductal

mitoxantrone has been researched along with Carcinoma, Ductal in 1 studies

Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.

Carcinoma, Ductal: Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zhang, B1
Fu, D1
Xu, Q1
Cong, X1
Wu, C1
Zhong, X1
Ma, Y1
Lv, Z1
Chen, F1
Han, L1
Qian, M1
Chin, YE1
Lam, EW1
Chiao, P1
Sun, Y1

Other Studies

1 other study available for mitoxantrone and Carcinoma, Ductal

ArticleYear
The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1.
    Nature communications, 2018, 04-30, Volume: 9, Issue:1

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal; Carcinoma, Non-Small-Cell Lung;

2018